Pharmacokinetic considerations for angiogenesis inhibitors used to treat hepatocellular carcinoma: an overview
出版年份 2023 全文链接
标题
Pharmacokinetic considerations for angiogenesis inhibitors used to treat hepatocellular carcinoma: an overview
作者
关键词
-
出版物
Expert Opinion on Drug Metabolism & Toxicology
Volume -, Issue -, Pages 1-10
出版商
Informa UK Limited
发表日期
2023-10-17
DOI
10.1080/17425255.2023.2272598
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Regorafenib loaded self-assembled lipid-based nanocarrier for colorectal cancer treatment via lymphatic absorption
- (2023) Dengning Xia et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
- (2023) Mathew Vithayathil et al. Hepatology International
- Are patients with hepatocellular carcinoma and portal vein tumour thrombosis candidates for liver transplantation?
- (2023) Arvinder Soin et al. JOURNAL OF HEPATOLOGY
- Unveiling the therapeutic potential of cabozantinib-loaded poly D,L-lactic-co-glycolic acid and polysarcosine nanoparticles in inducing apoptosis and cytotoxicity in human HepG2 hepatocellular carcinoma cell lines and in vivo anti-tumor activity in SCID female mice
- (2023) Sankha Bhattacharya et al. Frontiers in Oncology
- Survival outcomes from Atezolizumab plus Bevacizumab versus Lenvatinib versus Sorafenib in Child Pugh B unresectable hepatocellular carcinoma patients
- (2023) Margherita Rimini et al. JOURNAL OF HEPATOLOGY
- Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function
- (2022) Giuseppe Cabibbo et al. DIGESTIVE AND LIVER DISEASE
- Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child–Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial
- (2022) Anthony B. El-Khoueiry et al. BMC CANCER
- Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study
- (2022) Antonio D’Alessio et al. HEPATOLOGY
- Influence of schisantherin A on the pharmacokinetics of lenvatinib in rats and its potential mechanism
- (2022) Yanjun Cui et al. Journal of Gastrointestinal Oncology
- Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study
- (2022) Claudia Angela Maria Fulgenzi et al. EUROPEAN JOURNAL OF CANCER
- The impact of proton-pump inhibitors administered with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma
- (2022) Sebastiano Buti et al. ANTI-CANCER DRUGS
- Hepatocellular carcinoma
- (2021) Josep M. Llovet et al. Nature Reviews Disease Primers
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- The Effect of Concomitant Proton Pump Inhibitor and Cabozantinib on the Outcomes of Patients with Metastatic Renal Cell Carcinoma
- (2021) Elie Rassy et al. ONCOLOGIST
- Self-assembled phospholipid-based mixed micelles for improving the solubility, bioavailability and anticancer activity of lenvatinib
- (2021) Shuangshuang Zhang et al. COLLOIDS AND SURFACES B-BIOINTERFACES
- Resubclassification and clinical management for Barcelona Clinic Liver Cancer Stage C hepatocellular carcinoma
- (2021) Chih-Wen Lin et al. Hepatology International
- Lenvatinib as First-line Treatment of Hepatocellular Carcinoma in Patients with Impaired Liver Function in Advanced Liver Cirrhosis: Real World Data and Experience of a Tertiary Hepatobiliary Center
- (2021) Lidia-Sabina Cosma et al. Journal of Gastrointestinal and Liver Diseases
- Lentinan as a natural stabilizer with bioactivities for preparation of drug–drug nanosuspensions
- (2021) Zili Suo et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- Nanotechnology of Tyrosine Kinase Inhibitors in Cancer Therapy: A Perspective
- (2021) Eleonora Russo et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Bioequivalence and Pharmacokinetic Evaluation of Two Oral Formulations of Regorafenib: An Open-Label, Randomised, Single-Dose, Two-Period, Two-Way Crossover Clinical Trial in Healthy Chinese Volunteers Under Fasting and Fed Conditions
- (2021) Qian Zhang et al. Drug Design Development and Therapy
- Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region
- (2021) Colby S. Shemesh et al. Liver Cancer
- Novel Microcrystal Formulations of Sorafenib Facilitate a Long-Acting Antitumor Effect and Relieve Treatment Side Effects as Observed With Fundus Microcirculation Imaging
- (2021) Junxiao Wang et al. Frontiers in Oncology
- Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma – The Changing Tides
- (2021) Abdul Rehman Khan et al. Journal of Hepatocellular Carcinoma
- Adaptation of lenvatinib treatment in patients with hepatocellular carcinoma and portal vein tumor thrombosis
- (2021) Takanori Mukozu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Improving regorafenib's organ target precision via nano-assembly to change its delivery mode abolishes chemoresistance and liver metastasis of colorectal cancer
- (2021) Jia Liu et al. JOURNAL OF COLLOID AND INTERFACE SCIENCE
- Systemic treatment of hepatocellular carcinoma: An EASL position paper
- (2021) Jordi Bruix et al. JOURNAL OF HEPATOLOGY
- Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
- (2021) Ann-Lii Cheng et al. JOURNAL OF HEPATOLOGY
- Baicalin Enhanced Oral Bioavailability of Sorafenib in Rats by Inducing Intestine Absorption
- (2021) Jingyao Wei et al. Frontiers in Pharmacology
- Microbiome Crosstalk in Immunotherapy and Antiangiogenesis Therapy
- (2021) Xueting Wan et al. Frontiers in Immunology
- BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
- (2021) Maria Reig et al. JOURNAL OF HEPATOLOGY
- The effect of proton pump inhibitors on survival outcomes in advanced hepatocellular carcinoma treated with sorafenib
- (2020) Warit Ruanglertboon et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessment of lenvatinib treatment for unresectable hepatocellular carcinoma with liver cirrhosis
- (2020) Shohei Komatsu et al. HPB
- Discordance Between Child‐Pugh and National Cancer Institute Classifications for Hepatic Dysfunction: Implications on Dosing Recommendations for Oncology Compounds
- (2020) Mohamed Elmeliegy et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials
- (2020) Álvaro Díaz‐González et al. LIVER INTERNATIONAL
- Pharmacogenomics, Pharmacokinetics and Circulating Proteins As Biomarkers for Bevacizumab Treatment Optimization in Patients with Cancer: A Review
- (2020) Apostolos Papachristos et al. Journal of Personalized Medicine
- FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma
- (2020) Abhilasha Nair et al. ONCOLOGIST
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Andrew X Zhu et al. LANCET ONCOLOGY
- Minimal impact of hepatic and renal impairment on plasma protein binding of lenvatinib, and identification of its major plasma binding protein
- (2019) Yuji Mano et al. BIOPHARMACEUTICS & DRUG DISPOSITION
- Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers
- (2019) Lucia Cerrito et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma
- (2019) Elena De Mattia et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Tutorial on Monoclonal Antibody Pharmacokinetics and its Considerations in Early Development
- (2018) Meric Ovacik et al. CTS-Clinical and Translational Science
- Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation
- (2018) Erika Cecchin et al. DRUG RESISTANCE UPDATES
- Differential effects of hepatic cirrhosis on the intrinsic clearances of sorafenib and imatinib by CYPs in human liver
- (2018) Michael Murray et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Survival and tolerance to sorafenib in Child-Pugh B patients with hepatocellular carcinoma: a prospective study
- (2018) Cassia Regina Guedes Leal et al. INVESTIGATIONAL NEW DRUGS
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Influence of the proton pump inhibitor esomeprazole on the bioavailability of regorafenib:a randomized cross-over pharmacokinetic study
- (2018) Femke M. de Man et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Epidemiology and Management of Hepatocellular Carcinoma
- (2018) Laura Kulik et al. GASTROENTEROLOGY
- Clinical Pharmacokinetic and Pharmacodynamic Profile of Lenvatinib, an Orally Active, Small-Molecule, Multitargeted Tyrosine Kinase Inhibitor
- (2017) Ziad Hussein et al. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- The outcome of sorafenib monotherapy on hepatocellular carcinoma with portal vein tumor thrombosis
- (2017) Yuan-Hung Kuo et al. INVESTIGATIONAL NEW DRUGS
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Population pharmacokinetics of bevacizumab in cancer patients with external validation
- (2016) Kelong Han et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients
- (2016) Morgane Caulet et al. CLINICAL PHARMACOKINETICS
- Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib
- (2016) Steven A. Lacy et al. CLINICAL PHARMACOKINETICS
- Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Cabozantinib
- (2016) Linh Nguyen et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study
- (2016) Jorge A. Marrero et al. JOURNAL OF HEPATOLOGY
- Improving Oral Bioavailability of Sorafenib by Optimizing the “Spring” and “Parachute” Based on Molecular Interaction Mechanisms
- (2016) Chengyu Liu et al. MOLECULAR PHARMACEUTICS
- Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive review
- (2016) Kichang Han WORLD JOURNAL OF GASTROENTEROLOGY
- Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models
- (2016) Dieter Zopf et al. Cancer Medicine
- Lenvatinib – A multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer
- (2016) Yvonne Hewett et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects
- (2015) Linh Nguyen et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Lower Exposure and Faster Clearance of Bevacizumab in Gastric Cancer and the Impact of Patient Variables: Analysis of Individual Data from AVAGAST Phase III Trial
- (2014) Kelong Han et al. AAPS Journal
- Effect of Rifampicin on the Pharmacokinetics of Lenvatinib in Healthy Adults
- (2014) Robert C. Shumaker et al. CLINICAL DRUG INVESTIGATION
- Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers
- (2014) Robert Shumaker et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Influence of hepatic impairment on lenvatinib pharmacokinetics following single-dose oral administration
- (2014) Robert Shumaker et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Systemic Therapy for Hepatocellular Carcinoma: The Issue of Treatment Stage Migration and Registration of Progression Using the BCLC-Refined RECIST
- (2014) Maria Reig et al. SEMINARS IN LIVER DISEASE
- Vascular Invasion in Hepatocellular Carcinoma
- (2013) Yun-Hsuan Lee et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Influence ofFCGRTgene polymorphisms on pharmacokinetics of therapeutic antibodies
- (2013) Christophe Passot et al. mAbs
- Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based therapy
- (2013) N. Faruk Aykan et al. MEDICAL ONCOLOGY
- Soluplus-coated colloidal silica nanomatrix system for enhanced supersaturation and oral absorption of poorly water-soluble drugs
- (2013) Min-Soo Kim Artificial Cells Nanomedicine and Biotechnology
- Portal hemodynamic effects of sorafenib in patients with advanced hepatocellular carcinoma: a prospective cohort study
- (2012) Hisashi Hidaka et al. JOURNAL OF GASTROENTEROLOGY
- Bioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat
- (2011) Xue-qing Wang et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Saturable absorption of sorafenib in patients with solid tumors: a population model
- (2011) Marilyne Hornecker et al. INVESTIGATIONAL NEW DRUGS
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- Functional and Clinical Evidence of the Influence of Sorafenib Binding to Albumin on Sorafenib Disposition in Adult Cancer Patients
- (2011) Michel Tod et al. PHARMACEUTICAL RESEARCH
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- (2010) Scott M. Wilhelm et al. INTERNATIONAL JOURNAL OF CANCER
- Bevacizumab
- (2010) F. Kazazi-Hyseni et al. ONCOLOGIST
- Clinical pharmacokinetics of tyrosine kinase inhibitors
- (2009) Nielka P. van Erp et al. CANCER TREATMENT REVIEWS
- Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice
- (2009) B. Blanchet et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Clinical pharmacokinetics of bevacizumab in patients with solid tumors
- (2008) Jian-Feng Lu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction
- (2008) Roger K. Verbeeck EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started